AstraZeneca PLC (AZN)vsNutex Health Inc (NUTX)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
NUTX
Nutex Health Inc
$135.10
+1.71%
HEALTHCARE · Cap: $927.61M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 6768% more annual revenue ($60.44B vs $879.95M). AZN leads profitability with a 17.2% profit margin vs 11.0%. NUTX trades at a lower P/E of 9.9x. NUTX earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
NUTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+63.6%
Fair Value
$283.22
Current Price
$135.10
$148.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Attractively priced relative to earnings
Strong operational efficiency at 37.5%
Earnings expanding 95.9% YoY
Every $100 of equity generates 28 in profit
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
2.2% revenue growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : NUTX
The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : NUTX
The primary concerns for NUTX are Revenue Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while NUTX is a value play — different risk/reward profiles.
NUTX carries more volatility with a beta of 2.06 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 64/100), backed by strong 17.2% margins and 12.5% revenue growth. NUTX offers better value entry with a 63.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nutex Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?